Drug Trial Radar · NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
680
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
May 16, 2033
Study completion Jan 26, 2038
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Oct 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
PembrolizumabBiological
IV Infusion
CisplatinDrug
IV infusion
CarboplatinDrug
IV infusion
PemetrexedDrug
IV infusion
GemcitabineDrug
IV infusion
PaclitaxelDrug
IV infusion
Intismeran autogeneBiological
IM injection
PlaceboOther
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS)Time frame: Up to ~97 months
Locations
247 sites in 31 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0181)
Gilbert, Arizona · Recruiting
The University of Arizona Cancer Center - North Campus ( Site 0163)
Tucson, Arizona · Recruiting
Providence St. Jude Medical Center ( Site 0106)
Fullerton, California · Recruiting
VA Long Beach Healthcare System ( Site 0199)
Long Beach, California · Recruiting
USC Norris Comprehensive Cancer Center ( Site 0205)
Los Angeles, California · Recruiting
UCLA Jonsson Comprehensive Cancer Center ( Site 0135)
Los Angeles, California · Recruiting
UCSF Medical Center at Mission Bay ( Site 0178)
San Francisco, California · Recruiting
University of Colorado Anschutz Medical Campus ( Site 0151)
Aurora, Colorado · Recruiting
UCHealth Memorial Hospital Central ( Site 0125)
Colorado Springs, Colorado · Recruiting
Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207)
Greeley, Colorado · Recruiting
Centura Health - St. Anthony North Health Campus ( Site 0189)
Westminster, Colorado · Recruiting
Yale University School of Medicine ( Site 0201)
New Haven, Connecticut · Recruiting
Eastern CT Hematology & Oncology Associates ( Site 0202)
Norwich, Connecticut · Recruiting
The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156)
Fort Lauderdale, Florida · Recruiting
Miami Cancer Institute at Baptist Health, Inc. ( Site 0214)
Miami, Florida · Recruiting
Beacon Cancer Care ( Site 0127)
Post Falls, Idaho · Recruiting
The University of Chicago Medical Center ( Site 0118)
Chicago, Illinois · Recruiting
Hope and Healing Cancer Services ( Site 9527)
Hinsdale, Illinois · Recruiting
Illinois Cancer Care ( Site 8107)
Peoria, Illinois · Recruiting
Franciscan Health ( Site 0219)
Indianapolis, Indiana · Recruiting
Maryland Oncology Hematology (MOH) ( Site 8102)
Rockville, Maryland · Recruiting
Massachusetts General Hospital ( Site 0136)
Boston, Massachusetts · Recruiting
Dana Farber Cancer Hospital ( Site 0155)
Boston, Massachusetts · Recruiting
Ellis Fischel Cancer Center ( Site 0133)
Columbia, Missouri · Completed
Lake Regional Hospital-Cancer Center ( Site 0123)
Osage Beach, Missouri · Completed
Roswell Park Cancer Institute ( Site 0184)
Buffalo, New York · Recruiting
Hematology-Oncology Associates of CNY ( Site 0164)
East Syracuse, New York · Recruiting
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216)
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai ( Site 0116)
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0137)
New York, New York · Recruiting
SUNY Upstate Cancer Center ( Site 0140)
Syracuse, New York · Recruiting
Montefiore Medical Center ( Site 0160)
The Bronx, New York · Recruiting
Westchester Medical Center ( Site 0196)
Valhalla, New York · Recruiting
Novant Health Weisiger Cancer Insititute ( Site 0266)
Charlotte, North Carolina · Recruiting
Novant Health Forsyth Medical Center ( Site 0166)
Winston-Salem, North Carolina · Recruiting
University of Cincinnati Medical Center ( Site 0119)
Cincinnati, Ohio · Recruiting
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217)
Corvallis, Oregon · Recruiting
St. Lukes Hospital and Health Network ( Site 0186)
Bethlehem, Pennsylvania · Recruiting
Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315)
Chattanooga, Tennessee · Recruiting
Thompson Cancer Survival Center ( Site 0168)
Knoxville, Tennessee · Recruiting
Showing 40 of 247 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.